Review of gastric cancer risk factors in patients with common variable immunodeficiency disorders, resulting in a proposal for a surveillance programme

Clinical and Experimental Immunology

Volumn 165, Issue 1, 2011, Pages 1-7

  Dhalla, F ^a   da Silva, S P ^b   Lucas, M ^c   Travis, S ^d   Chapel, H ^c  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^b HOSPITAL DE SANTA MARIA   (Portugal)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Common variable immunodeficiency disorders (CVIDs); Gastric cancer; H. pylori; Pernicious anaemia; Surveillance

Indexed keywords

CYANOCOBALAMIN; IRON;

ACHLORHYDRIA; ATROPHIC GASTRITIS; AUTOIMMUNITY; BLOOD GROUP A; CANCER RISK; CANCER SCREENING; CARDIA; CHRONIC GASTRITIS; CLINICAL PROTOCOL; COMMON VARIABLE IMMUNODEFICIENCY; CYANOCOBALAMIN DEFICIENCY; ENVIRONMENTAL FACTOR; ERADICATION THERAPY; ESOPHAGUS CARCINOMA; FOLLOW UP; GASTROINTESTINAL ENDOSCOPY; GENDER; GENETIC PREDISPOSITION; HELICOBACTER INFECTION; HEREDITY; HIGH RISK POPULATION; HUMAN; IMMUNOSURVEILLANCE; INTESTINE METAPLASIA; LIFESTYLE; MEDICAL HISTORY; MEGALOBLASTIC ANEMIA; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NATURAL KILLER CELL; PEPTIC ULCER; PERNICIOUS ANEMIA; PRIORITY JOURNAL; PROGNOSIS; REGULATORY T LYMPHOCYTE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SENSITIVITY AND SPECIFICITY; SMOKING; SOCIAL STATUS; SQUAMOUS CELL CARCINOMA; STOMACH BIOPSY; STOMACH CANCER; STOMACH CARCINOGENESIS;

ANEMIA, PERNICIOUS; BACTERIAL INFECTIONS; COMMON VARIABLE IMMUNODEFICIENCY; EARLY DETECTION OF CANCER; GREAT BRITAIN; HUMANS; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; SEER PROGRAM; STOMACH NEOPLASMS;

EID: 79958169794     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2011.04384.x     Document Type: Review

References (55)

1. Fevang B, Yndestad A, Damas JK etal. Chemokines and common variable immunodeficiency; possible contribution of CCL19, CCL21 and CCR7 to immune dysregulation. Clin Exp Immunol 2009; 158:237-45.
2. Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol 1999; 93:190-7.
3. Chapel H, Cunningham-Rundles C. Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions. Br J Haematol 2009; 145:709-27.
4. Zullo A, Romiti A, Rinaldi V etal. Gastric pathology in patients with common variable immunodeficiency. Gut 1999; 45:77-81.
5. Chapel H, Lucas M, Lee M etal. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood 2008; 112:277-86.
6. Daniels JA, Lederman HM, Maitra A, Montgomery EA. Gastrointestinal tract pathology in patients with common variable immunodeficiency (CVID): a clinicopathologic study and review. Am J Surg Pathol 2007; 31:1800-12.
7. Yap YL, So JB. Gastric adenocarcinoma occurring in a young patient with common variable immunodeficiency syndrome. Singapore Med J 2009; 50:e201-3.
8. Lamers CB, Jansen JB. Hypogammaglobulinaemia and gastric cancer. Lancet 1985; 1:1100-1.
9. Conley ME, Ziegler MM, Borden St, Huff DS, Boyle JT. Multifocal adenocarcinoma of the stomach in a child with common variable immunodeficiency. J Pediatr Gastroenterol Nutr 1988; 7:456-60.
10. Mellemkjaer L, Hammarstrom L, Andersen V etal. Cancer risk among patients with IgA deficiency or common variable immunodeficiency and their relatives: a combined Danish and Swedish study. Clin Exp Immunol 2002; 130:495-500.
11. Desar IM, Keuter M, Raemaekers JM, Jansen JB, van Krieken JH, van der Meer JW. Extranodal marginal zone (MALT) lymphoma in common variable immunodeficiency. Neth J Med 2006; 64:136-40.
12. Delia M, Liso V, Capalbo S etal. Common variable immunodeficiency patient with large granular lymphocytosis developing extranodal diffuse large B-cell lymphoma: a case report. Haematologica 2006; 91 (Suppl.):ECR61.
13. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
14. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol 2006; 12:354-62.
15. Berrino F, Gatta G, Sant M, Capocaccia R. The EUROCARE study of survival of cancer patients in Europe: aims, current status, strengths and weaknesses. Eur J Cancer 2001; 37:673-7.
16. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24:2137-50.
17. Hamashima C, Shibuya D, Yamazaki H etal. The Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol 2008; 38:259-67.
18. Lee KJ, Inoue M, Otani T, Iwasaki M, Sasazuki S, Tsugane S. Gastric cancer screening and subsequent risk of gastric cancer: a large-scale population-based cohort study, with a 13-year follow-up in Japan. Int J Cancer 2006; 118:2315-21.
19. Miyamoto A, Kuriyama S, Nishino Y etal. Lower risk of death from gastric cancer among participants of gastric cancer screening in Japan: a population-based cohort study. Prev Med 2007; 44:12-9.
20. Talley NJ, Fock KM, Moayyedi P. Gastric Cancer Consensus conference recommends Helicobacter pylori screening and treatment in asymptomatic persons from high-risk populations to prevent gastric cancer. Am J Gastroenterol 2008; 103:510-14.
21. Wilson JM, Jungner YG. [Principles and practice of mass screening for disease]. Bol Oficina Sanit Panam 1968; 65:281-393.
22. Moller H, Heseltine E, Vainio H. Working group report on schistosomes, liver flukes and Helicobacter pylori. Int J Cancer 1995; 60:587-9.
23. Working Group. Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum 1994; 61:1-241.
24. Correa P, Haenszel W, Cuello C etal. Gastric precancerous process in a high risk population: cohort follow-up. Cancer Res 1990; 50:4737-40.
25. Sipponen P, Kekki M, Seppala K, Siurala M. The relationships between chronic gastritis and gastric acid secretion. Aliment Pharmacol Ther 1996; 10 (Suppl. 1):103-18.
26. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process - First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992; 52:6735-40.
27. Forman D, Webb P, Parsonnet J. H. pylori and gastric cancer. Lancet 1994; 343:243-4.
28. Danesh J. Helicobacter pylori infection and gastric cancer: systematic review of the epidemiological studies. Aliment Pharmacol Ther 1999; 13:851-6.
29. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001; 49:347-53.
30. Ruddell WS, Bone ES, Hill MJ, Blendis LM, Walters CL. Gastric-juice nitrite. A risk factor for cancer in the hypochlorhydric stomach? Lancet 1976; 2:1037-9.
31. Ruddell WS, Bone ES, Hill MJ, Walters CL. Pathogenesis of gastric cancer in pernicious anaemia. Lancet 1978; 1:521-3.
32. Yeomans ND, Brimblecombe RW, Elder J etal. Effects of acid suppression on microbial flora of upper gut. Dig Dis Sci 1995; 40 (Suppl.):S81-95.
33. Varis K. Surveillance of pernicious anaemia. In: Sherlock P, Morson BC, Barbara L, Veronesi V, eds. Precancerous lesions of the gastrointestinal tract. New York: Raven Press, 1983.
34. Hsing AW, Hansson LE, McLaughlin JK etal. Pernicious anemia and subsequent cancer. A population-based cohort study. Cancer 1993; 71:745-50.
35. Ye W, Nyren O. Risk of cancers of the oesophagus and stomach by histology or subsite in patients hospitalised for pernicious anaemia. Gut 2003; 52:938-41.
36. Kinlen LJ, Webster AD, Bird AG etal. Prospective study of cancer in patients with hypogammaglobulinaemia. Lancet 1985; 1:263-6.
37. Borriello SP, Reed PJ, Dolby JM, Barclay FE, Webster AD. Microbial and metabolic profile of achlorhydric stomach: comparison of pernicious anaemia and hypogammaglobulinaemia. J Clin Pathol 1985; 38:946-53.
38. Quinti I, Soresina A, Spadaro G etal. Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency. J Clin Immunol 2007; 27:308-16.
39. Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol 1999; 92:34-48.
40. Vajdic CM, Mao L, van Leeuwen MT, Kirkpatrick P, Grulich AE, Riminton S. Are antibody deficiency disorders associated with a narrower range of cancers than other forms of immunodeficiency? Blood 2010; 116:1228-34.
41. Desar IM, van Deuren M, Sprong T etal. Serum bactericidal activity against Helicobacter pylori in patients with hypogammaglobulinaemia. Clin Exp Immunol 2009; 156:434-9.
42. Twomey JJ, Jordan PH, Jarrold T, Trubowitz S, Ritz ND, Conn HO. The syndrome of immunoglobulin deficiency and pernicious anemia. A study of ten cases. Am J Med 1969; 47:340-50.
43. Park SY, Jeon SW, Jung MK etal. Long-term follow-up study of gastric intraepithelial neoplasias: progression from low-grade dysplasia to invasive carcinoma. Eur J Gastroenterol Hepatol 2008; 20:966-70.
44. Dinis-Ribeiro M, Lopes C, da Costa-Pereira A, Moreira-Dias L. We would welcome guidelines for surveillance of patients with gastric atrophic chronic and intestinal metaplasia! Helicobacter 2008; 13:75-6.
45. Horn J, Manguiat A, Berglund LJ etal. Decrease in phenotypic regulatory T cells in subsets of patients with common variable immunodeficiency. Clin Exp Immunol 2009; 156:446-54.
46. Giovannetti A, Pierdominici M, Mazzetta F etal. Unravelling the complexity of T cell abnormalities in common variable immunodeficiency. J Immunol 2007; 178:3932-43.
47. Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 2010; 125:1354-60 e4.
48. Fock KM, Talley N, Moayyedi P etal. Asia-Pacific consensus guidelines on gastric cancer prevention. J Gastroenterol Hepatol 2008; 23:351-65.
49. Mera R, Fontham ET, Bravo LE etal. Long term follow up of patients treated for Helicobacter pylori infection. Gut 2005; 54:1536-40.
50. de Vries AC, Haringsma J, Kuipers EJ. The detection, surveillance and treatment of premalignant gastric lesions related to Helicobacter pylori infection. Helicobacter 2007; 12:1-15.
51. Calvet X, Sanchez-Delgado J, Montserrat A etal. Accuracy of diagnostic tests for Helicobacter pylori: a reappraisal. Clin Infect Dis 2009; 48:1385-91.
52. Hooton C, Keohane J, Clair J etal. Comparison of three stool antigen assays with the 13C- urea breath test for the primary diagnosis of Helicobacter pylori infection and monitoring treatment outcome. Eur J Gastroenterol Hepatol 2006; 18:595-9.
53. Gisbert JP, Pajares JM. Stool antigen test for the diagnosis of Helicobacter pylori infection: a systematic review. Helicobacter 2004; 9:347-68.
54. Niv Y. H. pylori recurrence after successful eradication. World J Gastroenterol 2008; 14:1477-8.
55. Dinis-Ribeiro M, Lopes C, da Costa-Pereira A etal. A follow up model for patients with atrophic chronic gastritis and intestinal metaplasia. J Clin Pathol 2004; 57:177-82.